Information, Community and Research Funding
The mission of The EHE Foundation is to seek treatments and a cure for Epithelioid Hemangioendothelioma (EHE) by increasing awareness, pursuing scientific research, advocating for and supporting EHE patients, and bridging information between researchers, providers and patients.
HOW TO FIGHT EHE
As the season of giving and gratefulness approaches, we want to thank you for being a part of The EHE Foundation family. We appreciate you following our progress and investing in our passion: discovering effective treatments and a cure for EHE (Epithelioid Hemangioendothelioma). We appreciate our supporters, partners, and volunteers who make our continued progress possible.
#GivingTuesday is a global movement to celebrate and encourage giving after Thanksgiving, Black Friday, and Cyber Monday. We are thrilled to announce that donations up to $20,000 will be DOUBLED on #GivingTuesday (Tuesday, November 28th) through December 4th by two of our generous supporters. This is your chance to double your impact in helping those affected by this extremely rare cancer by donating online at www.FightEHE.org, through our Facebook Page https://www.facebook.com/Ehefoundation/, or by sending a check to The EHE Foundation, 1561 Hopi Ct, Hobart, WI 54313.
You can trust that your contribution will go a long way in continuing our forward momentum in research for EHE. The EHE Foundation is a non-profit organization operated entirely by volunteers, who are dedicated to advocating for and supporting EHE patients. We know you have many options when it comes to giving, but we hope you will support those affected by EHE.
If you would like to discuss how to donate time, goods, or services, or if you need assistance, please e-mail firstname.lastname@example.org.
With deep respect and gratitude,
The EHE Foundation
IMPORTANT EHE NEWS & TRIALS
Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That Is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery.
ClinicalTrials.gov Identifier: NCT03148275
For the last several years Dr.Brian Rubin has been working on unlocking genetic driving mechanism behind EHE progression. His work resulted in identification of a pathway directly involved in supporting of EHE genetic malfunction .During the Lab experiments, Dr Rubin was able to disrupt this pathway with MEK inhibitor.
The clinical trial uses MEK inhibitor Mekinist. The purpose of the study to verify that what Dr.Rubin observed in his Lab actually translates in clinical effect in EHE patients. It is a multi institutional study which makes it very easy for enrolment in different parts of the country. You can see more information using following link.
FAQs for P10015, SARC033 – Phase II trial of trametinib in patients with unresectable or metastatic epithelioid hemangioendothelioma (EHE). Is there a point at ...
Axitinib and Pembrolizumab Trial
Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas
ClinicalTrials.gov Identifier: NCT02636725
This is the only immunotherapy study currently listing EHE as designated sarcoma. Immunotherapy drug Pembrolizumab( Keytruda) is combined with anti angiogenic drug Axitinib.Both groups of drugs showed some effect in EHE patients. Their combination already presented synergetic effect in other cancers. Immunotherapy is gaining momentum and Dr. Breelyn Wilky from Sylvester Cancer Center in Miami is one of the leading immuno oncologists in sarcoma. She is a Primary Investigator in this trial. The study is conducted only in Miami. You can see more information using following link.